- Home
- COCH vs BNR Comparison
COCH vs BNR Comparison
Compare COCH & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- BNR
- Stock Information
- Founded
- COCH 1995
- BNR 2014
- Country
- COCH United States
- BNR China
- Employees
- COCH N/A
- BNR N/A
- Industry
- COCH Blank Checks
- BNR Medical Specialities
- Sector
- COCH Finance
- BNR Health Care
- Exchange
- COCH Nasdaq
- BNR Nasdaq
- Market Cap
- COCH 31.6M
- BNR 29.1M
- IPO Year
- COCH N/A
- BNR 2020
- Fundamental
- Price
- COCH $1.50
- BNR $3.86
- Analyst Decision
- COCH Strong Buy
- BNR
- Analyst Count
- COCH 2
- BNR 0
- Target Price
- COCH $9.25
- BNR N/A
- AVG Volume (30 Days)
- COCH 20.0K
- BNR 35.7K
- Earning Date
- COCH 08-11-2025
- BNR 08-21-2025
- Dividend Yield
- COCH N/A
- BNR N/A
- EPS Growth
- COCH N/A
- BNR N/A
- EPS
- COCH N/A
- BNR N/A
- Revenue
- COCH $212,000.00
- BNR $72,112,038.00
- Revenue This Year
- COCH $8.04
- BNR $136.32
- Revenue Next Year
- COCH $15.39
- BNR N/A
- P/E Ratio
- COCH N/A
- BNR N/A
- Revenue Growth
- COCH N/A
- BNR 0.53
- 52 Week Low
- COCH $1.21
- BNR $2.18
- 52 Week High
- COCH $3.99
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- COCH 57.76
- BNR 62.38
- Support Level
- COCH $1.40
- BNR $3.06
- Resistance Level
- COCH $1.58
- BNR $3.50
- Average True Range (ATR)
- COCH 0.08
- BNR 0.23
- MACD
- COCH 0.01
- BNR 0.03
- Stochastic Oscillator
- COCH 100.00
- BNR 87.26
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.